Table 1. Patient baseline characteristics.
| Variable | 1 mg/kg (n=6) | 3 mg/kg (n=8) | 10 mg/kg (n=6) | Total (n=20) | PD-L1 ≥1% (n=9) | PD-L1 <1% (n=11) |
|---|---|---|---|---|---|---|
| Median age [range] | 45 [39–55] | 53 [38–60] | 50 [33–60] | 48.5 [33–60] | 44 [33–51] | 53 [38–60] |
| ECOG PS (n, %) | ||||||
| 0 | 3 (50.0) | 6 (75.0) | 6 (100.0) | 15 (75.0) | 7 (77.8) | 8 (72.7) |
| 1 | 3 (50.0) | 2 (25.0) | 0 | 5 (25.0) | 2 (22.2) | 3 (27.3) |
| Metastatic sites (n, %) | ||||||
| Visceral (± nonvisceral) | 6 (100.0) | 5 (62.5) | 3 (50.0) | 14 (70.0) | 7 (77.8) | 7 (63.6) |
| Liver | 1 (16.7) | 2 (25.0) | 2 (33.3) | 5 (25.0) | 3 (33.3) | 2 (18.2) |
| Lung | 5 (83.3) | 3 (37.5) | 1 (16.7) | 9 (45.0) | 3 (33.3) | 6 (54.5) |
| Bone | 2 (33.3) | 3 (37.5) | 2 (33.3) | 7 (35.0) | 3 (33.3) | 4 (36.4) |
| Brain | 0 | 0 | 0 | 0 | 0 | 0 |
| Nonvisceral only | 0 | 3 (37.5) | 3 (50.0) | 6 (30.0) | 2 (22.2) | 4 (36.4) |
| Number of systemic chemotherapy lines for metastatic disease (n, %) | ||||||
| Median [range] | 2.5 [1–5] | 2.5 [1–4] | 1.5 [0–3] | 2 [0–5] | 2 [1–4] | 2 [0–5] |
| 0 | 0 | 0 | 1 (16.7) | 1 (5.0) | 0 | 1 (9.0) |
| 1 | 2 (33.3) | 2 (25.0) | 2 (33.3) | 6 (30.0) | 4 (44.4) | 2 (18.2) |
| 2 | 1 (16.7) | 2 (25.0) | 2 (33.3) | 5 (25.0) | 2 (22.2) | 3 (27.3) |
| ≥3 | 3 (50.0) | 4 (50.0) | 1 (16.7) | 8 (40.0) | 3 (33.3) | 5 (45.5) |
| Previous therapy (n, %) | ||||||
| Taxanes | 6 (100.0) | 8 (100.0) | 6 (100.0) | 20 (100.0) | 9 (100.0) | 11 (100.0) |
| Anthracyclines | 6 (100.0) | 6 (75.0) | 6 (100.0) | 18 (90.0) | 9 (100.0) | 9 (81.8) |
| Platinum | 6 (100.0) | 7 (87.5) | 5 (83.3) | 18 (90.0) | 8 (88.9) | 10 (90.9) |
| Capecitabine | 4 (66.7) | 6 (75.0) | 4 (66.7) | 14 (70.0) | 5 (55.6) | 9 (81.8) |
| Vinorelbine | 4 (66.7) | 4 (50.0) | 1 (16.7) | 9 (45.0) | 3 (33.3) | 6 (54.5) |
| Gemcitabine | 4 (66.7) | 5 (62.5) | 3 (50.0) | 12 (60.0) | 5 (55.6) | 7 (63.6) |